00:11 , Aug 18, 2018 |  BioCentury  |  Product Development

Doing more with less

In rare diseases where natural history data are scarce, Phase II studies may have to perform dual duty to both seek efficacy signals and test out new endpoints. Ovid Therapeutics Inc. and Clementia Pharmaceuticals Inc....
00:20 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Ovid's Angelman syndrome candidate misses behavior, sleep and gait endpoints in Phase II

Ovid Therapeutics Inc. (NASDAQ:OVID) reported that gaboxadol (OV101) failed to significantly improve prespecified efficacy measures of behavior, sleep and gait in the Phase II STARS trial to treat Angelman syndrome. The company said one dose...
21:07 , Aug 6, 2018 |  BC Extra  |  Clinical News

Ovid falls on Phase II data for Angelman syndrome candidate

Ovid Therapeutics Inc. (NASDAQ:OVID) fell $3.44 (36%) to $6.08 on Monday after reporting that gaboxadol (OV101) failed to significantly improve prespecified efficacy measures of behavior, sleep and gait in the Phase II STARS trial to...
00:07 , Dec 22, 2017 |  BC Innovations  |  Strategy

Ovid spreads its wings

With its first two candidates for rare neurological disorders heading towards clinical proof of concept, Ovid Therapeutics Inc. is looking to capitalize on the experience it has gained to find compounds with differentiated pharmacology that...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
00:00 , May 6, 2017 |  BC Extra  |  Financial News

Ovid dips in first trading day

Ovid Therapeutics Inc. (NASDAQ:OVID) fell $2.75 (18%) to $12.25 in its first day of trading Friday. The company priced its $75 million IPO after market hours on Thursday (see BioCentury Extra, May 4). The company's lead...
23:50 , May 4, 2017 |  BC Extra  |  Financial News

Ovid prices $75M IPO

Neurological disease company Ovid Therapeutics Inc. (NASDAQ:OVID) raised $75 million through the sale of 5 million shares at $15 in an IPO underwritten by Citigroup, Cowen, William Blair and JMP Securities. The price valued the...
19:57 , Apr 11, 2017 |  BC Extra  |  Financial News

Ovid planning $86.3M IPO

Neurologic disease company Ovid Therapeutics Inc. (New York, N.Y.) proposed to raise $86.3 million in an IPO on NASDAQ underwritten by Citigroup, Cowen, William Blair and JMP Securities. On Monday, Ovid said it began a Phase...
20:16 , Feb 17, 2017 |  BC Week In Review  |  Company News

Ovid Therapeutics, Stemina deal

Ovid and Stemina's NeuroPointDX diagnostics division partnered to identify biomarkers associated with Angelman Syndrome to assess patient responses to Ovid's gaboxadol (OV101). The collaboration will use NeuroPointDX’s metabolomics technology to evaluate data from the ongoing...
21:19 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Gaboxadol: Ph II STARS started

Ovid began the double-blind, placebo-controlled, U.S. Phase II STARS trial to evaluate once- and twice-daily oral gaboxadol in about 75 patients. Ovid has exclusive, worldwide rights to gaboxadol from Lundbeck under a 2015 deal (see...